EUVIMEDOdkrijte EUVIMED
Open access

Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia

Brad Spellberg, Roger J Lewis, Helen W Boucher, Eric P Brass

Clinical Investigation · 2011

DOI: 10.4155/cli.10.1 ↗

At a glance

Journal article in Clinical Investigation, 2011. Written by Brad Spellberg and 3 co-authors. Institution: Division of General Internal Medicine, Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-University of California Los Angeles (UCLA) Me…. Cited 11 times so far (Crossref); 57 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Standards for the conduct of clinical trials of antibacterial agents for community-acquired bacterial pneumonia (CABP) have changed dramatically in recent years. A draft guidance from the US FDA on the conduct of such trials was issued in March 2009. However, the guidance has already faced substantial criticism during the open public comment period, resulting in uncertainty regarding the appropriate design of such studies from a regulatory perspective. Controversies regarding the magnitude of the treatment effect associated with antibacterial therapy versus placebo/no therapy, the appropriate timing, nature and noninferiority margin for the primary efficacy end point, and other clinical and statistical issues have complicated efforts to reach consensus on appropriate trial design of antibacterial therapy for CABP. It is critical that studies of new drugs for CABP are designed to ensure that they are feasible to conduct and that their results are scientifically valid, statistically rigorous and clinically meaningful. Based on 3 years of active dialog between clinical, statistical, and regulatory experts, this article proposes an approach to enable a balance of clinical trial feasibility with appropriate scientific, statistical and clinical rigor.

Authors and institutions

  • Division of General Internal Medicine, Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-University of California Los Angeles (UCLA) Medical Center, CA, USA.

Funding

  • NIAID NIH HHS

Cite

APA

Spellberg, B., Lewis, R. J., Boucher, H. W., & Brass, E. P. (2011). Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia. Clinical Investigation. https://doi.org/10.4155/cli.10.1

Vancouver

Spellberg B, Lewis RJ, Boucher HW, Brass EP. Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia. Clinical Investigation. 2011. doi:10.4155/cli.10.1

BibTeX
@article{Spellberg2011,
  author = {Spellberg, Brad and Lewis, Roger J and Boucher, Helen W and Brass, Eric P},
  title = {Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia},
  journal = {Clinical Investigation},
  year = {2011},
  doi = {10.4155/cli.10.1}
}
Start for free →